{"id":"W2921877205","doi":"10.1093/jcag/gwz006.121","title":"A122 COMBINATION BIOLOGIC THERAPY IN INFLAMMATORY BOWEL DISEASE: THE CALGARY EXPERIENCE","year":2019,"lang":"en","type":"article","venue":"Journal of the Canadian Association of Gastroenterology","topic":"Microscopic Colitis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Vedolizumab; Infliximab; Golimumab; Adalimumab; Ustekinumab; Ulcerative colitis; Internal medicine; Inflammatory bowel disease; Faecal calprotectin; Crohn's disease; Combination therapy; Biologic Agents; Certolizumab pegol; Gastroenterology; Disease; Calprotectin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001180017,0.0004429083,0.000517963,0.0006840178,0.0007349643,0.001195284,0.0005902624,0.000679532,0.002511301],"category_scores_gemma":[0.00151785,0.0002719544,0.0003508593,0.001509262,0.0007935702,0.0005890782,0.001069852,0.001558422,0.0006940528],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001696645,"about_ca_system_score_gemma":0.001586923,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009859352,"about_ca_topic_score_gemma":0.01778769,"domain_scores_codex":[0.9990797,0.0002844346,0.00006165197,0.0001485283,0.0002785291,0.0001470936],"domain_scores_gemma":[0.9989285,0.0002921071,0.0001612577,0.00009717466,0.0001223087,0.0003986243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.002921088,0.002846539,0.1582376,0.0007708019,0.0002992038,0.01169357,0.001794235,0.0005079746,0.006728265,0.001062574,0.01716769,0.7959706],"study_design_scores_gemma":[0.00251088,0.01757258,0.6987576,0.00142348,0.0006842018,0.06479079,0.001546702,0.000817686,0.002974124,0.0006851486,0.2081152,0.0001214821],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7749239,0.1905921,0.001069537,0.005885855,0.0005187825,0.0002026893,0.0002639765,0.00005082248,0.02649239],"genre_scores_gemma":[0.8521533,0.1330225,0.002189588,0.005132505,0.001233991,0.00007843884,0.0004878716,0.00005019052,0.005651664],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009859352,"threshold_uncertainty_score":0.01960391,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006995530574416766,"score_gpt":0.2350238210076898,"score_spread":0.228028290433273,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}